Resumes & CV records
Resumes
David A Tabaczynski, 53Cohasset, MA
David Tabaczynski Phones & Addresses
Cohasset, MA
45 Fletcher Hill Ln, Groton, MA 01450 978-4490263
18 Bromfield Rd, Acton, MA 01720 978-2637725
223 Edgebrook Dr, Boylston, MA 01505 508-8693319
Framingham, MA
Philadelphia, PA
Boston, MA
Rochester, NY
Lovettsville, VA
Clinton Twp, MI
Social networks
David A Tabaczynski
Linkedin
Mentions for David A Tabaczynski
Publications & IP owners
Us Patents
Phage-Derived Vectors And Methods For Protein Expression
US Patent:
2009031, Dec 17, 2009
Filed:
Feb 17, 2006
Appl. No.:
11/884591
Inventors:
David Tabaczynski - Groton MA, US
International Classification:
C12P 21/06
C12N 7/00
C12N 15/74
C12N 1/21
C12N 7/00
C12N 15/74
C12N 1/21
US Classification:
435 691, 4352351, 435475, 4352523
Abstract:
A novel system, including vectors, particles, host cells and methods of use, for expressing one or more polypeptides of interest in prokaryotes is described.
Inhibition Of Isoprenoid Biosynthetic Pathways To Treat Autoimmune Disorders
US Patent:
2016037, Dec 29, 2016
Filed:
Dec 1, 2014
Appl. No.:
15/039888
Inventors:
David A. TABACZYNSKI - Cohasset MA, US
International Classification:
A61K 31/662
A61K 31/663
A61K 31/56
A61K 31/65
A61K 31/18
A61K 31/16
A61K 31/519
A61K 45/06
A61K 31/663
A61K 31/56
A61K 31/65
A61K 31/18
A61K 31/16
A61K 31/519
A61K 45/06
Abstract:
The invention provides methods and pharmaceutical compositions that can treat autoimmune disease by reducing the production of pyrophosphate intermediates produced during the biosynthesis of isoprenoids. The pyrophosphate compounds being inhibited are normally produced through the mevalonate and non-mevalonate pathways of the host vertebrate organisms and their symbiotic and pathogenic microorganisms. The methods involve administering to a patient an inhibitor of the mevalonate-dependent pathway, an inhibitor of the non-mevalonate pathway, or combination of such inhibitors.
Inhibition Of Isoprenoid Biosynthetic Pathways To Treat Neuroinflammatory Disorders
US Patent:
2016030, Oct 20, 2016
Filed:
Dec 12, 2014
Appl. No.:
15/102680
Inventors:
David A. TABACZYNSKI - Cohasset MA, US
International Classification:
A61K 31/662
A61K 31/56
A61K 31/66
A61K 45/06
A61K 31/519
A61K 31/56
A61K 31/66
A61K 45/06
A61K 31/519
Abstract:
This invention provides methods and pharmaceutical compositions that can treat neuroinflammatory disease by reducing the production of pyrophosphate intermediates produced during the biosynthesis of isoprenoids. The pyrophosphate compounds being inhibited are normally produced through the mevalonate and non-mevalonate pathways of the host vertebrate organisms and their symbiotic and pathogenic microorganisms. The methods involve administering to a patient an inhibitor of the mevalonate-dependent pathway, an inhibitor of the non-mevalonate pathway, or combination of such inhibitors.
Cap And Ingredient For Multi-Compartment Container
US Patent:
2014020, Jul 31, 2014
Filed:
Jan 28, 2014
Appl. No.:
14/165746
Inventors:
- Boston MA, US
David Tabaczynski - Cohasset MA, US
David Tabaczynski - Cohasset MA, US
International Classification:
B65D 47/36
US Classification:
206222
Abstract:
A cap for a container includes a depressible structure arranged such that, when the depressible structure is depressed, the depressible structure applies force onto a first compartment, thereby rupturing the first compartment and dispensing a first ingredient into a second compartment of the container. The depressible structure can include a pliant material. Also described is a solid material shaped to concentrate force applied by the depressible structure at a first location of the first compartment to facilitate rupturing the first compartment. Additionally described is an ingredient that includes an effervescent material.
NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.